|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for KAT2A |
 Gene summary |
| Basic gene Info. | Gene symbol | KAT2A |
| Gene name | K(lysine) acetyltransferase 2A | |
| Synonyms | GCN5|GCN5L2|PCAF-b|hGCN5 | |
| Cytomap | UCSC genome browser: 17q21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_021078.2, | |
| Description | GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2General control of amino acid synthesis, yeast, homolog-like 2STAF97general control of amino acid synthesis protein 5-like 2histone acetyltransferase GCN5histone acetyltransferase K | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602301 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000108773 | ||
| HPRD : 03807 | ||
| Vega : OTTHUMG00000133504 | ||
| Protein | UniProt: Q92830 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_KAT2A | |
| BioGPS: 2648 | ||
| Pathway | NCI Pathway Interaction Database: KAT2A | |
| KEGG: KAT2A | ||
| REACTOME: KAT2A | ||
| Pathway Commons: KAT2A | ||
| Context | iHOP: KAT2A | |
| ligand binding site mutation search in PubMed: KAT2A | ||
| UCL Cancer Institute: KAT2A | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0016578 | histone deubiquitination | 18206972 | GO:0043966 | histone H3 acetylation | 10373431 |
| Top |
| Ligand binding site mutations for KAT2A |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L531 | R533H | COAD | 1 | T592 | H593L | COAD | 1 | I576 | T574A | HNSC | 1 | V581 | T582N | UCEC | 1 | Y617 | A618T | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for KAT2A |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | T592 | H593L | 0.34769808 | L531 | R533H | -1.4357633 | Y617 | A618T | -0.87812571 | V581 | T582N | -0.76563682 | I576 | T574A | -0.73213997 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for KAT2A from PDB |
| Top |
| Differential gene expression and gene-gene network for KAT2A |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for KAT2A |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for KAT2A |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Nutraceutical | DB01992 | Coenzyme A | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of KAT2A go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ACO | ACETYL COENZYME *A | 1z4r | A | L531 I576 V581 T592 Y617 |
| Top |
| Conservation information for LBS of KAT2A |
| Multiple alignments for Q92830 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |